Lipocine

Lipocine is a biopharmaceutical company based in Salt Lake City, Utah. It leverages a proprietary technology platform to develop innovative products with effective oral delivery, aiming to enable differentiated, patient-friendly oral options with favorable benefit-to-risk profiles targeting large addressable markets with significant unmet medical needs. Its proprietary technology is based on a lipidic composition that forms an optimal drug nano dispersion in the gastrointestinal tract, enabling improved portal and/or lymphatic absorption of highly water-insoluble drugs. Its pipeline includes LPCN 1154 (BRLIZIO), under development for postpartum depression, and LPCN 2201, with therapeutic targets including postpartum depression, major depressive disorder, epilepsy, essential tremor, cirrhosis, obesity management, preterm birth, and hypogonadism.

Lipocine is a biopharmaceutical company based in Salt Lake City, Utah. It leverages a proprietary technology platform to develop innovative products with effective oral delivery. Its proprietary technology is based on a lipidic composition that forms an optimal drug nano dispersion in the gastrointestinal tract, enabling improved portal and/or lymphatic absorption of highly water-insoluble drugs. The company's pipeline includes LPCN 1154 (BRLIZIO), under development for postpartum depression (PPD) treatment targeting rapid relief with a 48-hour oral treatment, and LPCN 2201. Its therapeutic targets include postpartum depression, major depressive disorder, epilepsy, essential tremor, cirrhosis, obesity management, preterm birth, and hypogonadism. In 2026, Lipocine announced the initiation of the BLOOM Phase 3 study of LPCN 1154 for postpartum depression, reported topline safety and efficacy results for LPCN 1154 in patients with postpartum depression, and announced that LPCN 1154 Phase 3 data were accepted for oral presentation at the 2026 ASCP Annual Meeting. The company also announced the appointment of Michael J. Grissinger to its Board of Directors.

Patient-friendly oral therapy options with favorable benefit-risk profiles, enabled by a proprietary lipidic drug-delivery technology platform.

• LPCN 1154 (BRLIZIO)

  Under development for postpartum depression (PPD) treatment targeting rapid relief with a 48-hour oral treatment; also described as a convenient fast-acting, non-dissociative oral antidepressant.

• LPCN 2201

  Listed among Lipocine's pipeline and product presentations.

• 2021

  Lipocine and Clarus enter global settlement agreement

  Lipocine and Clarus Therapeutics entered into a global settlement agreement to resolve outstanding claims in their intellectual-property litigation and an interference proceeding between the companies.

  Source

• 2020

  Judge postpones Lipocine–Clarus patent trial

  Judge William C. Bryson of the U.S. District Court of Delaware postponed the jury trial scheduled for February 8, 2021, in Lipocine's patent litigation against Clarus Therapeutics because of the ongoing effects of the COVID-19 pandemic. Lipocine alleges that Clarus's JATENZO product infringes its U.S. patents; the trial is to be rescheduled when jury trials resume in the district.

  Source

Read more

1. 1Home | Lipocinelipocine.com
2. 2About Lipocine | Lipocinelipocine.com
3. 3Corporate Governance | Lipocinelipocine.com
4. 4Careers | Lipocinelipocine.com
5. 5Lipocine (United States)wikidata.org
6. 6Judge postpones Lipocine–Clarus patent trialprnewswire.com
7. 7Lipocine and Clarus enter global settlement agreementprnewswire.com
8. 8Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applicationsprnewswire.com